Acepodia to Present Preclinical Data on its Gamma Delta T cell Therapy Candidate, ACE1831, at 2022 SITC Annual Meeting |
| November 03, 2022 | November 2022 Bond Updates |
|
ALAMEDA, Calif., and TAIPEI, Nov. 3, 2022 /PRNewswire/ -- Acepodia, a clinical-stage biotechnology company developing first-in-class cell therapies with its unique antibody-cell conjugation (ACC) technology to address gaps in cancer care, today announced the upcoming poster presentation... |
| View more at: https://www.prnewswire.com:443/news-releases/acepodia-to-present-preclinical-data-on-its-gamma-delta-t-cell-therapy-candidate-ace1831-at-2022-sitc-annual-meeting-301667249.html |
| Related News |
|